The immunotherapy drug Tecentriq (atezolizumab) was approved earlier this year by the U.S. Food and Drug Administration to treat patients with newly diagnosed non-small cell lung cancers (NSCLC), which comprise up to 85% of all lung tumors.
from WebMD Healthhttps://img.webmd.com/dtmcms/live/webmd/consumer_assets/site_images/article_thumbnails/blog_posts/cancer/metastatic_lung_cancer_blog/1800x1200_metastatic_lung_cancer_blog.jpg https://ift.tt/2GoGlJ9
via IFTTT
0 comments:
Post a Comment